Discovering and developing best-in-class long acting therapeutic proteins
Long-Acting Therapeutic Proteins
Ambrx’s technology enables the site-specific conjugation of pharmacokinetic (PK) half-life extenders to maintain the time of action of therapeutic proteins in patients
The efficacy of many therapeutic proteins is limited by instability and short half-life in circulation, which can result in poor drug performance. Conventional techniques for improving the half-life of therapeutic peptides and proteins have generally been limited to genetic fusion proteins or non-specific conjugations. The Ambrx technology is not restricted to
convenient attachment sites that may reduce product stability or efficacy, but rather enables the rapid design and assessment of sites across the protein surface to produce bio-conjugates with optimal qualities. By linking the half-life extenders at systematically optimized positions, we can make bioconjugates that are stable and highly effective.
Ambrx’s ReCODE™ technology enables the site-specific conjugation of a PK extender at any position within a polypeptide chain so as to create a single homogenous molecule with properties that can be tuned to meet the target product profile. Our bio-conjugates are optimized for both functional activity and half-life. This technology is well suited to select from a variety of PK extenders including polyethylene glycol (PEG), lipids and other polymers. Using our Protein Medicinal Chemistry™ approach, we rapidly identify the best site for conjugation of each PK extender, delivering the optimal combination of safety, efficacy, biophysical properties and half-life.
ARX-201: PEGylated hGH binding to its receptor: